SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 22, 2023--
Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment. Collectively, the posters will report data from more than 60,000 patients. The meeting will take place in Washington, DC, from November 28 to December 1.
The American Cancer Society estimates that there will be nearly 290,000 new cases of prostate cancer in the U.S. this year. An ongoing challenge in the management of prostate cancer is distinguishing between patients whose tumors require careful monitoring, known as active surveillance, and those who require intervention. Routinely used clinical factors, such as Gleason score and prostate-specific antigen (PSA) level, are not sufficient to determine which prostate cancers are likely to progress and which are not.
“These presentations by users of the Decipher Prostate Genomic Classifier will add to the growing body of clinical evidence supporting the use of the test to help physicians guide care for their patients with prostate cancer,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. “This breadth of real-world data truly distinguishes our genomic classifier from other molecular tests available today and serves as a strong foundation for using Decipher results to provide a more complete understanding of each patient’s cancer for more personalized care.”
The following posters will be presented at the SUO 2023 meeting on Friday, December 1:
Title: Assessing molecular heterogeneity of prostate cancer biopsy sampling: Insights from the MAST trial
Presenter: Tarek Ajami, M.D., University of Miami
Poster: #214
Time: 10 a.m. to 11 a.m. ET
Title: Decipher® Genomic Classifier on initial prostate biopsy is associated with Gleason score upgrading on final radical prostatectomy pathology
Presenter: John Sheng, M.D., Washington University School of Medicine in St. Louis
Poster: #226
Time: 12:45 p.m. to 1:45 p.m. ET
Title: Decipher® Genomic Classifier score on initial biopsy is associated with progression from active surveillance to treatment in prostate cancer
Presenter: John Sheng, M.D., Washington University School of Medicine in St. Louis
Poster: #237
Time: 1:45 p.m. to 2:45 p.m. ET
Title: Does genomic risk score at biopsy correlate with focality of disease at radical prostatectomy: Implications for focal therapy candidates
Presenter: Jenna Winebaum, M.D., University of California, San Francisco
Poster: #189
Time: 9 a.m. to 10 a.m. ET
Title: Grade and volume progression and its association with the Decipher Genomic Classifier using patients enrolled in a prospective active surveillance protocol
Presenter: Archan Khandekar, M.D., University of Miami
Poster: #219
Time: 12:45 p.m. to 1:45 p.m. ET
Title: Molecular correlates with PSMA expression in primary prostate cancer
Presenter: Adam B. Weiner, M.D., University of California, Los Angeles
Poster: #201
Time: 10 a.m. to 11 a.m. ET
Title: Understanding population-wide genomic risk distribution and integrating clinical-genomic risk for prognostication in patients with clinically localized prostate cancer
Presenter: Udit Singhal, M.D., University of Michigan
Poster: #200
Time: 9 a.m. to 10 a.m. ET
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," “positioned,” “designed” and similar references to future periods. Examples of forward-looking statements include, among others, that the breadth of real-world data supporting the Decipher Prostate Genomic Classifier serves as a strong foundation for using Decipher results to provide a more complete understanding of each patient’s cancer for more personalized care. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on March 1, 2023, and our Quarterly Report on Form 10-Q filed for the three months ended June 30, 2023. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.
Veracyte, the Veracyte logo, and Decipher are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries.
Decipher Prostate is available in the US as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the FDA. Veracyte, the Veracyte logo, and Decipher are registered trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and selected countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231122731608/en/
Investors:
investors@veracyte.com
619-393-1545
Media:
Tracy Morris
VP of Global Corporate Communications
tracy.morris@veracyte.com
650-380-4413
Source: Veracyte, Inc.